secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cogent Biosciences, Inc. (COGT)
CIK:        0001622229
Form:       8-K
Filed at:   2024-03-22T23:59:59+00:00
Accession:  0001193125-24-074628
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 3.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cogent Biosciences exchanges 8.3M common shares for Series B non-voting convertible preferred
--------------------------------------------------------------------------------

- 8,300,000 common shares exchanged for 8,300 Series B Preferred convertible into 20,580,000 common shares.
- Exchange closes March 25, 2024; Series B has no voting rights except on amendments to its preferences.
- Post-exchange common outstanding: 95,613,396; Series A Preferred convertible into 18,616,250 common shares.
- Issued under Section 3(a)(9) exemption; no registration required.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1622229/000119312524074628/0001193125-24-074628-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1622229/000119312524074628/d796451d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-074628

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer